Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE II: Quetiapine XR + Integrated Care in Schizophrenia
NCT00681629Phase 4Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of quetiapine in schizophrenia, schizoaffective disorder and schizophreniform disorder (2 arms), sponsored by AstraZeneca. Primary endpoint: Subjective Well-being Under Neuroleptics Scale at 4 months. Started Jul 2008; status: terminated.
02
Drugs
quetiapine
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT00681629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681629.